Sign Up for a Free Account
  • Updated 01.26.2024
  • Released 12.13.2018
  • Expires For CME 01.26.2027

Hereditary amyloid polyneuropathy



Hereditary amyloidosis is a disease caused by mutations in the transthyretin gene that leads to systemic deposition of amyloid protein. Although patients have multisystem involvement of amyloidosis, cardiomyopathy and peripheral neuropathy with autonomic neuropathy are typically the most prominent disease manifestations and the primary drivers of disability and mortality. Small interfering RNA, or antisense oligonucleotide therapies approved by the United States Food and Drug Administration, reduce the production of transthyretin protein and slow the progression of hereditary amyloid polyneuropathy and, in some cases, improve measures of neuropathy severity and associated disability. Although hereditary transthyretin amyloidosis is a rare disease, it is an exciting model for developing new treatments for genetic disease in neurology and in medicine broadly.

Key points

• Hereditary amyloid polyneuropathy primarily refers to patients with mutations in the transthyretin gene, although mutations in other genes may present with amyloidosis and neuropathy.

• The symptoms of transthyretin-associated familial amyloid polyneuropathy are those of a sensory or sensorimotor polyneuropathy, with progressive sensory loss and weakness, often with prominent autonomic neuropathy. Neuropathy is often accompanied by amyloid cardiomyopathy.

• hATTR polyneuropathy is diagnosed and confirmed with genetic testing for TTR gene mutations. Amyloidosis may be detected on tissue biopsy in the workup of idiopathic neuropathy or cardiomyopathy, which may lead to suspicion of a genetic diagnosis.

• Small interfering RNA and antisense oligonucleotide therapies that reduce or “silence” TTR gene expression are effective treatments to slow the progression of hATTR polyneuropathy.

Historical note and terminology

Rudolf Virchow first described amyloid deposits in 1858, noting their starch-like appearance and reaction to iodine and sulfuric acid. Congo red staining of amyloid was first described in 1922, and the typical apple-green birefringence was noted in 1927 in patients with Alzheimer disease (48).

Transthyretin protein is named in reference to its two primary transport functions: binding thyroxine and retinol-binding protein (45). The TTR gene was sequenced in 1974 by Kanda and colleagues; at that time the transthyretin protein was referred to as plasma thyroxine-binding prealbumin (32). In 1991, Benson described 10 TTR gene mutations associated with familial amyloid polyneuropathy (14). The number of TTR gene mutations associated with disease has grown. More than 140 mutations in the TTR gene have been described (

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125